Susan G. Komen® does not conduct its own scientific research but has funded more breast cancer research than any other nonprofit — more than $1 billion to date. We fund along the entire breast cancer continuum, which includes studies into prevention, early detection, aggressive breast cancers (like triple negative and metastatic breast cancer), and the development of new treatments, including new drugs, to treat the disease.

The U.S. Food and Drug Administration (FDA) requires that any new pharmaceutical compound be tested on at least two different animal models to be considered for approval for use in humans. Therefore, some investigators must conduct animal testing in order to comply with FDA regulations for drug development.

As part of our grants oversight process, Komen requires these investigators to provide proof of pre-approval of study design and animal care methods from the Institutional Animal Care and Use Committee (IACUC) at the institution where they will be conducting research. IACUC assurances, available at this link: http://iacuc.org, are intended to limit animal research to only that which is unavoidable and to limit animal discomfort and injury.

We take this compliance very seriously as part of our grants review and monitoring process.

May 2018